Liver Fibrosis, Inflammation & Oxidative Stress Markers
肝纤维化、炎症
基本信息
- 批准号:7101927
- 负责人:
- 金额:$ 12.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-27 至 2007-08-31
- 项目状态:已结题
- 来源:
- 关键词:alcoholic liver cirrhosisbiomarkerbiopsyclinical researchcollagenasecytochrome P450enzyme activityhistopathologyhuman tissueinflammationkeratinlamininmalonaldehydeoxidative stressperoxidationprocollagentenascintissue inhibitor of metalloproteinasestransforming growth factorstumor necrosis factor alpha
项目摘要
DESCRIPTION (provided by applicant):
Liver cirrhosis is a major cause of mortality in alcoholics. Recent experimental pathophysiotogic studies suggest several therapeutic approaches but their clinical verification is hampered by the requirement of liver biopsies to establish the stage of the disease, the therapeutic indications and documentation of outcome. Various circulating markers have been proposed as substitute for biopsies. The specific aim of the present study is to validate these markers, taking advantage of over 2,000 sequential liver biopsies and corresponding blood samples collected in 789 alcoholics studied for up to 6 years in VA Cooperative Study 391, including monthly measurements of carbohydrate deficient transferrin to substantiate the self-reported alcohol consumption. This recently conducted trial assessed the effects of polyunsaturated phosphatidylcholine (PPC), a soybean extract, on alcoholic liver disease, with superimposed hepatitis C in 1/3 of the patients. The liver pathology varied from fatty liver to perivenular and septal fibrosis and cirrhosis, with variable degrees of inflammation. Correlation of these lesions with the following proposed circulating markers of fibrosis will be determined: laminin, tenascin, procollagen type tll and collagen IV and VI. The activity of enzymes that degrade fibrotic tissue, such as metalloproteinases and their inhibitors, will also be measured. In addition, hepatic parameters with the potential to prognosticate progression of liver disorders, such as cytokeratins, will be assessed. Cytokines that affect fibrogenesis as well as inflammation, e.g. TNFalpha and TGF-beta will also be evaluated. One major pathogenic factor is oxidative stress resulting from free radicals generated by alcohol-induced cytochrome P450 (CYP2E1). Accordingly, the correlation of markers of oxidative stress (4-hydroxynonenal, F2-isoprostanes and malondialdehyde) with the degree of CYP2E1 induction in the liver will be evaluated. Once validated, these markers could serve in future studies to detect subjects vulnerable to drugs activated to toxins by CYP2E1. As controls for the markers of a specific lesion (such as cirrhosis), we will use the values of the same markers in patients without the specific liver disease. In conclusion, an available bank of sequential liver biopsies and monthly blood samples, collected in association with detailed clinical information, offers a unique opportunity to establish which circulating markers can serve as partial substitute for liver biopsies, thereby optimizing the diagnosis, prevention and treatment of alcoholic liver injury.
描述(由申请人提供):
肝硬化是酗酒者死亡的主要原因。最近的实验性病理生理学研究提出了几种治疗方法,但其临床验证受到肝活检的要求,以确定疾病的阶段,治疗适应症和记录结果的阻碍。已经提出了各种循环标志物作为活检的替代品。本研究的具体目的是验证这些标志物,利用VA合作研究391中长达6年的789名酗酒者中收集的2,000多个连续肝活检和相应的血液样本,包括每月测量碳水化合物缺乏转铁蛋白以证实自我报告的酒精消费量。这项最近进行的试验评估了多不饱和磷脂酰胆碱(PPC),一种大豆提取物,对酒精性肝病的影响,其中1/3的患者合并丙型肝炎。肝脏病理学变化从脂肪肝到小静脉周围和间隔纤维化和肝硬化,伴有不同程度的炎症。将确定这些病变与以下提出的纤维化循环标志物的相关性:层粘连蛋白、腱生蛋白、tll型前胶原和胶原IV和VI。还将测量降解纤维化组织的酶的活性,例如金属蛋白酶及其抑制剂。此外,还将评估可能加速肝脏疾病进展的肝脏参数,如细胞角蛋白。还将评价影响纤维形成以及炎症的细胞因子,例如TNF α和TGF-β。一个主要的致病因素是由酒精诱导的细胞色素P450(CYP 2 E1)产生的自由基引起的氧化应激。因此,将评价氧化应激标志物(4-羟基壬烯醛、F2-异前列烷和丙二醛)与肝脏中CYP 2 E1诱导程度的相关性。一旦得到验证,这些标记物可以在未来的研究中用于检测易受CYP 2 E1毒素激活药物影响的受试者。作为特定病变(如肝硬化)标志物的对照,我们将使用无特定肝病患者的相同标志物值。 总之,一个可用的连续肝活检和每月血液样本库,收集与详细的临床信息,提供了一个独特的机会,以确定哪些循环标志物可以作为肝活检的部分替代品,从而优化诊断,预防和治疗酒精性肝损伤。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES S LIEBER其他文献
CHARLES S LIEBER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES S LIEBER', 18)}}的其他基金
Liver Fibrosis, Inflammation & Oxidative Stress Markers
肝纤维化、炎症
- 批准号:
6770660 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
Synergistic Nutraceutical Effects of DLPC and SAMe
DLPC 和 SAMe 的协同保健作用
- 批准号:
7024566 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
Synergistic Nutraceutical Effects of DLPC and SAMe
DLPC 和 SAMe 的协同保健作用
- 批准号:
6770613 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
Liver Fibrosis, Inflammation & Oxidative Stress Markers
肝纤维化、炎症
- 批准号:
6952293 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
Synergistic Nutraceutical Effects of DLPC and SAMe
DLPC 和 SAMe 的协同保健作用
- 批准号:
7204192 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
Synergistic Nutraceutical Effects of DLPC and SAMe
DLPC 和 SAMe 的协同保健作用
- 批准号:
6884085 - 财政年份:2004
- 资助金额:
$ 12.01万 - 项目类别:
ANTIVIRAL & ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS
抗病毒物质
- 批准号:
6211435 - 财政年份:2000
- 资助金额:
$ 12.01万 - 项目类别:
Antiviral/Antifibrotic Liver Therapy of HCV+ Drinkers
HCV 饮酒者的抗病毒/抗纤维化肝治疗
- 批准号:
7046265 - 财政年份:2000
- 资助金额:
$ 12.01万 - 项目类别:
ANTIVIRAL & ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS
抗病毒物质
- 批准号:
7064573 - 财政年份:2000
- 资助金额:
$ 12.01万 - 项目类别:
ANTIVIRAL & ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS
抗病毒物质
- 批准号:
6757147 - 财政年份:2000
- 资助金额:
$ 12.01万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 12.01万 - 项目类别:
Targeting pathologic macrophage activation through inhibition of MyD88 to attenuate laryngotracheal stenosis
通过抑制 MyD88 靶向病理性巨噬细胞激活以减轻喉气管狭窄
- 批准号:
10644555 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Etiology and pathogenesis of lethal lung developmental disorders in neonates
新生儿致命性肺发育障碍的病因和发病机制
- 批准号:
10660107 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Project 3: Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia/Cancer
项目3:绝经前妇女肥胖和子宫内膜增生/癌症的一级预防和子宫保留
- 批准号:
10711638 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
精氨酸消耗联合铂类紫杉烷化疗对侵袭性变异前列腺癌 (AVPC) 的影响
- 批准号:
10715329 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORS
描述同型半胱氨酸-叶酸-胸苷酸合成酶轴和尿嘧啶积累在非裔美国人前列腺肿瘤中的作用
- 批准号:
10723833 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver
肝脏肿瘤发生的超极化 13C 代谢成像
- 批准号:
10727760 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
NASH-肝细胞癌免疫治疗反应的决定因素
- 批准号:
10735947 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases
用于肝脏疾病细胞外囊泡高灵敏度和样品节省分析的质谱法
- 批准号:
10736006 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别:
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
晚期前列腺癌中 Trop-2 的分子调控和表达:确定最佳治疗领域
- 批准号:
10735996 - 财政年份:2023
- 资助金额:
$ 12.01万 - 项目类别: